PureTech Health’s Founded Entity Akili announces positive data from adult ADHD trial

James Spargo | May 4, 2023 | News story | Medical Communications ADHD, Akili, Neurology, PureTech Health, clinical trials 

Clinical-stage biotherapeutics company PureTech Health has reported that its Founded Entity Akili, a digital medicine company, has announced positive topline results from a clinical trial evaluating the efficacy and safety of its video game-based therapeutic for adults with Attention Deficit Hyperactive Disorder (ADHD).

EndeavorRx is the first and only US Food and Drug Administration (FDA)-authorised treatment delivered through video game form. For children, it is recommended to be used for around 25 minutes a day, five days a week, over at least four consecutive weeks, in combination with therapy, medication and/or educational programmes.

The STARS-ADHD-Adult trial enrolled 221 patients aged 18 or over with inattentive or combined-type ADHD. Patients used EndeavorRx on a mobile device at home for six weeks. Results showed that EndeavorEx “demonstrated a statistically significant improvement in the Test of Variables of Attention (TOVA)-Attention Comparison Score (ACS) of sustained and selective attention from baseline.” TOVA is a computerised test approved by the FDA to aid in ADHD diagnosis and to evaluate the effects of interventions.

Scott Kollins PhD, chief medical officer of Akili, stated: “Not only did the benefit of EndeavorRx in adults with ADHD exceed what we’ve seen in kids and adolescents, adults using the treatment experienced meaningful improvements in their quality of life. This data comes at a critical time when there is growing demand among adults with ADHD for safe, effective and accessible non-drug treatments. It is increasingly recognised that current available options are not working, and/or are not available. We are deeply committed to getting this treatment to patients as quickly as possible. We are evaluating regulatory strategies and look forward to sharing more soon.”

James Spargo

Related Content

PureTech Health launches Seaport Therapeutics

PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to …

Gilead and Merck share data from phase 2 trial of HIV treatment

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …

FDA clears Aruna Bio’s IND for AB126 to enter clinical trials

Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its …

Latest content